Tag: Cytidine deaminase
-

BioLineRx GLIX1 Patent Receipt: USPTO Notice of Allowance Expands Cancer Treatment Reach
BioLineRx Secures USPTO Notice of Allowance for GLIX1 Patent BioLineRx announced a pivotal milestone: the U.S. Patent and Trademark Office has issued a Notice of Allowance for the GLIX1 patent, covering its use in treating a broad spectrum of cancers. This development marks a significant step in protecting the company’s GLIX1-based therapeutic approach as it…
